These are the key facts you need to know about ARMD. There's no need to try and memorize them at this juncture; rather, over the course of this slide-set we will unpack/drill down on each, hopefully allowing you to absorb them without having to explicitly commit them to memory!

- ARMD is the #1 cause of blindness in adults age 50+ in resource-rich nations
- Age is the strongest risk factor for ARMD
- The clinical hallmark of ARMD is the presence of *drusen* in the macula
- There are two types of ARMD: Exudative and nonexudative
- RPE and photoreceptor abnormalities are common findings in ARMD
- The pathogenesis of ARMD is not well understood, but the complement system is strongly implicated in it
- The DDx for exudative ARMD is extensive, but the three top conditions are ocular histoplasmosis, angioid streaks, and pathologic myopia
- VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it
- Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts

 Key fact #1: ARMD is the #1 cause of blindness in adults age 50+ in resource-rich nations



(Not much unpacking to do with this one—it is what it is. Memorize and move on!)









Given its name, it should come as no surprise that *age is the strongest risk factor in ARMD.* It is estimated that 25% of Americans 75 and older have some degree of ARMD.





Given its name, it should come as no surprise that *age is the strongest risk* factor in ARMD. It is estimated that 25% of Americans 75 and older have some degree of ARMD. Other risk factors include race (non-Hispanic whites are at greatest risk; African-Americans, the lowest), family history, and light irides.





Given its name, it should come as no surprise that *age is the strongest risk* factor in ARMD. It is estimated that 25% of Americans 75 and older have some degree of ARMD. Other risk factors include race (non-Hispanic whites are at greatest risk; African-Americans, the lowest), family history, and light irides. The strongest *modifiable* risk factor is **smoking**.

 Key fact #3: The clinical hallmark of ARMD is the presence of drusen in the macula







Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle.



9

Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.





Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:







Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)




Small drusen



12

Intermediate drusen



Large drusen






Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By size (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

--'Hard' drusen (discrete, well demarcated boundaries)





Hard drusen

 Key fact #3: The clinical hallmark of ARMD is the presence of drusen in the macula



Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- --'Hard' drusen (discrete, well demarcated boundaries)
- --'Soft' drusen (amorphous, poorly demarcated boundaries)





Soft drusen






Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- --'Hard' drusen (discrete, well demarcated boundaries)
- -- 'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)



18

A, Color fundus photograph shows soft, **confluent**, large drusen in a patient with ARMD. **B**, Corresponding SD-OCT of the soft drusen. **C**, Autofluorescence image of an eye with areas of confluent drusen.





Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- ---'Hard' drusen (discrete, well demarcated boundaries)
- --'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located



Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- ---'Hard' drusen (discrete, well demarcated boundaries)
- --'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located

Before we get into specific drusen locations, let's take a moment to review the anatomy of the outer retina



We'll start with


Bruch's membrane



We'll start with


Bruch's membrane,


which is the structure that separates the retina from the choroid.






Bruch's membrane consists of 5 layers:







Bruch's membrane consists of 5 layers:


(**Note**: This line represents the RPE basement membrane)

- 1) Basement membrane of RPE
- 2) Inner collagenous layer
- 3) Elastic layer


Bruch's membrane


- 4) Outer collagenous layer
- 5) Basement membrane of choriocapillaris


(Note: This line represents the c'capillaris basement membrane)











1) Basement membrane of RPE

2) Inner collagenous layer


3) Elastic layer


Bruch's membrane


- 4) Outer collagenous layer
- 5) Basement membrane of choriocapillaris


Innermost

Outermost









 Key fact #3: The clinical hallmark of ARMD is the presence of drusen in the macula



Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:

By **size** (Small, Intermediate; Large)



Now we're ready to discuss retinal location as it relates to various types of drusen



--'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located:





Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:


By size (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- ---'Hard' drusen (discrete, well demarcated boundaries)
- --'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located:

--Basal laminar drusen are between the RPE cells and their basement membrane







Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:


By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- ---'Hard' drusen (discrete, well demarcated boundaries)
- ---'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located:

- --Basal laminar drusen are between the RPE cells and their basement membrane
- --Basal linear drusen are within the inner aspect of Bruch's membrane







Drusen are focal accumulations of material within the layers of the outer retina. The material is composed of a variety of (mainly) proteins and lipids—waste shed by photoreceptors (PRs) as by-products of the visual cycle. Drusen can alter the structural integrity of the outer retina in ways that produce local or widespread damage to PRs, resulting in significant vision loss.

Clinicians categorize drusen along several dimensions:


By **size** (Small, Intermediate; Large)

By the nature/appearance of their boundaries:

- --'Hard' drusen (discrete, well demarcated boundaries)
- ---'Soft' drusen (amorphous, poorly demarcated boundaries)
- ---'Confluent' drusen (contiguous drusen without clear boundaries)

By where in the retina they are located:

- --Basal laminar drusen are between the RPE cells and their basement membrane
- --Basal linear drusen are within the inner aspect of Bruch's membrane
- --Reticular pseudodrusen are between the apical surface of the RPE cells and the overlying PRs




 Key fact #4: There are two types of ARMD: Exudative and nonexudative







To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM).




3) Elastic la nous layer


Bruch's membrane


CNVM within Bruch's membrane

40

brane of choriocapillaris Choriocapillaris









FP and FA of a CNVM in exudative ARMD








To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced defects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the acute onset of a 'gray spot' in their vision. If untreated, subfoveal CNVM result in devastating, irreversible vision loss.






To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced defects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the acute onset of a 'gray spot' in their vision. If untreated, subfoveal CNVM result in devastating, irreversible vision loss.

Let's take a moment to review the blood supply of the retina












Here is a micrograph of a normal human retina. The **yellow line** depicts the level below which retinal vessels do not pass.






Here is a micrograph of a normal human retina. The yellow line depicts the level below which retinal vessels do not pass. Instead, the outer-retina cells receive O₂ via diffusion from the choroid.



Here is a micrograph of a normal human retina. The yellow line depicts the level below which retinal vessels do not pass. Instead, the outer-retina cells receive O_2 via diffusion from the choroid.

Remember: The normal outer retina has no blood vessels!


Figure 1: Optical Coherence Tomography Angiography of a Normal Eye Very important—this is an OCTA of a normal eye



Optical coherence tomography (OCT) angiograms and corresponding OCT B-scans of the (A) superficial inner retina, (B) deep inner retina, (C) outer retina, (D) choriocapillaris. Note the regular ovoid foveal avascular zone, and homogeneity of vascular density of the retinal vasculature and choriocapillaris.




Figure 1: Optical Coherence Tomography Angiography of a Normal Eye Very important—this is an OCTA of a normal eye



Optical coherence tomography (OCT) angiograms and corresponding OCT B-scans of the (A) superficial inner retina, (B) deep inner retina, (C) outer retina (D) choriocapillaris. Note the regular ovoid foveal avascular zone, and homogeneity of vascular distinct of the retinal vasculature and choriocapillaris.

Take special note of the **absence** of vascular structures within the outer retina.

Figure 1: Optical Coherence Tomography Angiography of a Normal Eye Very important—this is an OCTA of a normal eye




Optical coherence tomography (OCT) angiograms and corresponding OCT B-scans of the (A) superficial inner retina, (B) deep inner retina, (C) outer retina (D) choriocapillaris. Note the regular ovoid foveal avascular zone, and homogeneity of vascular distinct of the retinal vasculature and choriocapillaris.

Take special note of the **absence** of vascular structures within the outer retina. Again: This portion/layer of the retina is avascular under normal circumstances.




Figure 1: Optical Coherence Tomography Angiography of a Normal Eye



OCTA of the same layers, but in an eye with a CNVM




Figure 1: Optical Coherence Tomography Angiography of a Normal Eye



OCTA of the same layers, but <u>in an eye with a CNVM</u>. Note the presence of vasculature within the normally avascular outer retina (green circle). **This is a CNVM**.




Figure 1: Optical Coherence Tomography Angiography of a Normal Eye




OCTA of the same layers, but *in an eye with a CNVM*. Note the presence of vasculature within the normally avascular outer retina (green circle). This is a CNVM. You can see its origin in the choriocapillaris (blue circle).









CNVM: OCT (SRF = subretinal fluid)





To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced defects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the acute onset of a 'gray spot' in their vision. If untreated, subfoveal CNVM result in devastating, irreversible vision loss.


In contrast, *nonexudative* (aka *dry* or *non-neovascular*) ARMD is defined by the presence of drusen, RPE changes, and/or geographic atrophy (GA). In contrast with the sudden and severe loss of visual acuity (VA) associated with exudative dz, nonexudative ARMD is insidious, producing gradual VA loss of mild-to-moderate severity.

Key fact #4: There are two types of ARMD: Exudative and nonexudative



To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced defects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the acute onset of a 'gray spot' in their vision. If untreated, subfoveal CNVM result in devastating, irreversible vision loss.

In contrast, *nonexudative* (aka *dry* or *non-neovascular*) ARMD is defined by the presence of drusen, RPE changes, and/or geographic atrophy (GA). In contrast with the sudden and severe loss of visual acuity (VA) associated with exudative dz, nonexudative ARMD is insidious, producing gradual VA loss of mild-to-moderate severity. The exception is GA. *GA* refers to a sharply defined area of the posterior pole in which the RPE, overlying PRs, and underlying choriocapillaris are all atrophic.



Geographic atrophy (GA)






To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced defects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the acute onset of a 'gray spot' in their vision. If untreated, subfoveal CNVM result in devastating, irreversible vision loss.

In contrast, *nonexudative* (aka *dry* or *non-neovascular*) ARMD is defined by the presence of drusen, RPE changes, and/or geographic atrophy (GA). In contrast with the sudden and severe loss of visual acuity (VA) associated with exudative dz, nonexudative ARMD is insidious, producing gradual VA loss of mild-to-moderate severity. The exception is GA. *GA* refers to a sharply defined area of the posterior pole in which the RPE, overlying PRs, and underlying choriocapillaris are all atrophic. GA typically starts in the perifoveal region, expanding over time to first encircle and then involve the foveal center. Involvement of the foveal center produces VA loss as profound as that of exudative dz.





Progression of GA over a 2.5 year period. Note the characteristic perifoveal → foveal-center pattern.





To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced fects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the

Note: 'Advanced ARMD' is defined by the presence of either CNVM...

m acvasiaing, meversible vision ioss

In contrast, *nonexudative* (aka *dry* or *non-neovascular*) ARMD is defined by the presence of drusen, RPE changes, and/or geographic atrophy (GA). In contrast with the sudden and severe loss of visual acuity (VA) associated with exudative dz, nonexudative ARMD is insidious, producing gradual VA loss of mild-to-moderate severity. The exception is GA. *GA* refers to a sharply defined area of the posterior pole in which the RPE, overlying PRs, and underlying choriocapillaris are all atrophic. GA typically starts in the perifoveal region, expanding over time to first encircle and then involve the foveal center. Involvement of the foveal center produces VA loss as profound as that of exudative dz.





To say a case of ARMD is *exudative* (aka *wet* or *neovascular*) is to say that a frond of fibrovascular tissue has grown into a space where none should be: within Bruch's membrane, beneath the RPE, and/or in the subretinal space. Because they originate from choroidal vessels, these fronds are called *choroidal neovascular membranes* (CNVM). CNVM break into or through Bruch's membrane via drusen-induced fects within it. CNVM are highly prone to bleeding and/or leaking; when they do, pts usually experience the

Note: 'Advanced ARMD' is defined by the presence of either CNVM...or GA.

III ucvasiaiiig, iiicveisibie visioii ioss

In contrast, *nonexudative* (aka *dry* or *non-leovascular*) ARMD is defined by the presence of drusen, RPE changes, and or geographic atrophy (GA). In contrast with the sudden and severe loss of isual acuity (VA) associated with exudative dz, nonexudative ARMD is insidio 6, producing gradual VA loss of mild-to-moderate severity. The exception is **GA**. *GA* refers to a sharply defined area of the posterior pole in which the RPE, overlying PRs, and underlying choriocapillaris are all atrophic. GA typically starts in the perifoveal region, expanding over time to first encircle and then involve the foveal center. Involvement of the foveal center produces VA loss as profound as that of exudative dz.

 Key fact #5: RPE and photoreceptor abnormalities are common findings in ARMD





 Key fact #5: RPE and photoreceptor abnormalities are common findings in ARMD



A tremendous amount is known about ARMD, but much more remains to be discovered. Part of the challenge is, most of the changes that occur in ARMD—RPE atrophy; PR loss—are also seen in the normal aging process.



 Key fact #5: RPE and photoreceptor abnormalities are common findings in ARMD



A tremendous amount is known about ARMD, but much more remains to be discovered. Part of the challenge is, most of the changes that occur in ARMD—RPE atrophy; PR loss—are also seen in the normal aging process. It is not yet clear why some aging eyes go on to develop clinical ARMD whereas others do not.

 Key fact #6: The pathogenesis of ARMD is not well understood, but the complement system is strongly implicated in it



 Key fact #6: The pathogenesis of ARMD is not well understood, but the complement system is strongly implicated in it



There are two types of immune responses: *innate* (aka *natural*) and *adaptive* (aka *acquired*). The innate immune response relies on 'preprogrammed' immune cells (PMNs; macrophages) to recognize foreign material encountered in tissue or blood, whereas the adaptive response involves 'education,' with surveillance cells (T- and B-cells) learning to recognize and remember foreign antigens.

 Key fact #6: The pathogenesis of ARMD is not well understood, but the complement system is strongly implicated in it




There are two types of immune responses: *innate* (aka *natural*) and *adaptive* (aka *acquired*). The innate immune response relies on 'preprogrammed' immune cells (PMNs; macrophages) to recognize foreign material encountered in tissue or blood, whereas the adaptive response involves 'education,' with surveillance cells (T- and B-cells) learning to recognize and remember foreign antigens. However, neither immune system is capable of producing an effective response on its own. Instead, both rely on *inflammatory mediators*—host-generated substances that act as force-multipliers for the immune response. Inflammatory mediators can be a single molecule, or a complex enzymatic process.


 Key fact #6: The pathogenesis of ARMD is not well understood, but the complement system is strongly implicated in it



There are two types of immune responses: *innate* (aka *natural*) and *adaptive* (aka *acquired*). The innate immune response relies on 'preprogrammed' immune cells (PMNs; macrophages) to recognize foreign material encountered in tissue or blood, whereas the adaptive response involves 'education,' with surveillance cells (T- and B-cells) learning to recognize and remember foreign antigens. However, neither immune system is capable of producing an effective response on its own. Instead, both rely on *inflammatory mediators*—host-generated substances that act as force-multipliers for the immune response. Inflammatory mediators can be a single molecule, or a complex enzymatic process. The classic example of an enzymatic-cascade inflammatory mediator is the **complement cascade**. Activation of the complement cascade results in damage that is central in the pathogenesis of both dry and wet forms of ARMD. The complement cascade is indeed complex, with 30+ components comprising three different pathways. At present, research indicates that certain variants of **complement factor H** (CFH) are of particular significance in the development of ARMD. (If you remember nothing else from this slide, remember CFH.)







Complement cascade. Give this Figure a brief once-over, then move on. (It's intended to do nothing more than reinforce the fact that the complement cascade is complex indeed.)

 Key fact #7: The DDx for exudative ARMD is extensive, but the three top conditions are ocular histoplasmosis, angioid streaks, and pathologic myopia









OHS is an infectious posterior uveitis caused by the dimorphic fungus Histoplasma capsulatum. Bats and various bird species are the reservoir; spores in their droppings become aerosolized, infecting humans via inhalation.





H capsulatum: Mold (filamentous) form



H capsulatum: Yeast form

 Key fact #7: The DDx for exudative ARMD is extensive, but the three top conditions are ocular histoplasmosis, angioid streaks, and pathologic myopia




OHS is an infectious posterior uveitis caused by the dimorphic fungus Histoplasma capsulatum. Bats and various bird species are the reservoir; spores in their droppings become aerosolized, infecting humans via inhalation. OHS has two strong demographic predilections: 1) It occurs almost exclusively among whites of Northern European heritage; and 2) it is most likely to affect individuals residing in the Mississippi and Ohio River valleys.



Areas Endemic for Histoplasmosis









OHS is an infectious posterior uveitis caused by the dimorphic fungus *Histoplasma capsulatum.* Bats and various bird species are the reservoir; spores in their droppings become aerosolized, infecting humans via inhalation. OHS has two strong demographic predilections: 1) It occurs almost exclusively among whites of Northern European heritage; and 2) it is most likely to affect individuals residing in the Mississippi and Ohio River valleys. OHS is a clinical dx made by finding on DFE the so-called 'classic triad' of OHS:

- --Histo spots
- --Peripapillary atrophy
- --Disciform CNVM lesions (either active or old/inactive)







OHS: The classic triad






Active disciform lesion (ie, CNVM)



Inactive disciform lesion





The pathologic hallmark of angioid streaks is a thickened and brittle Bruch's membrane. These abnormalities make Bruch's prone to breakage, which in turn allows the ingress of choriocapillaris vessels forming a CNVM.


 Key fact #7: The DDx for exudative ARMD is extensive, but the three top conditions are ocular histoplasmosis, angioid streaks, and pathologic myopia




The pathologic hallmark of angioid streaks is a thickened and brittle Bruch's membrane. These abnormalities make Bruch's prone to breakage, which in turn allows the ingress of choriocapillaris vessels forming a CNVM. On DFE, angioid streaks appear as reddish-brown lines radiating out from the peripapillary region, which is usually atrophic.









Angioid streaks (arrowheads). Note that only a few of the many present have been marked.





The pathologic hallmark of angioid streaks is a thickened and brittle Bruch's membrane. These abnormalities make Bruch's prone to breakage, which in turn allows the ingress of choriocapillaris vessels forming a CNVM. On DFE, angioid streaks appear as reddish-brown lines radiating out from the peripapillary region, which is usually atrophic.

Half of cases are idiopathic; the rest are associated with systemic abnormalities. The well-known mnemonic for angioid streak's associations is *PEPSI*:

Pseudoxanthoma elasticum (PXE)

Ehlers-Danlos syndrome

Paget's disease of bone

Sickle-cell disease

Idiopathic (ie, no association)







An axial length of 26.5 mm is the cutoff for defining pathologic myopia. The finding on DFE that puts high myopes at risk for CNVM are *lacquer cracks*. Like angioid streaks, lacquer cracks are breaks in Bruch's membrane that provide an opening for CNVM to enter the outer retina.





An axial length of 26.5 mm is the cutoff for defining pathologic myopia. The finding on DFE that puts high myopes at risk for CNVM are *lacquer cracks*. Like angioid streaks, lacquer cracks are breaks in Bruch's membrane that provide an opening for CNVM to enter the outer retina. However, unlike the reddish color and peripapillary distribution of angioid streaks, lacquer cracks are yellowish in color and found in the macula.





Pathologic myopia: Lacquer cracks (note also the abnormal ONH appearance)

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

Because of its importance in CNVM formation, VEGF presents a potent target for therapies intended to interdict CNVM. A number of highly effective anti-VEGF compounds have been developed (and more are in the therapeutic pipeline).

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

Because of its importance in CNVM formation, VEGF presents a potent target for therapies intended to interdict CNVM. A number of highly effective anti-VEGF compounds have been developed (and more are in the therapeutic pipeline). Bevacizumab (brand name Avastin) is a recombinant monoclonal antibody against VEGF. Originally developed to treat metastatic cancer (by depriving it of its blood supply), bevacizumab is highly effective in causing both anatomic regression of CNVM as well as reversal of CNVM-induced VA loss.

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

Because of its importance in CNVM formation, VEGF presents a potent target for therapies intended to interdict CNVM. A number of highly effective anti-VEGF compounds have been developed (and more are in the therapeutic pipeline). Bevacizumab (brand name Avastin) is a recombinant monoclonal antibody against VEGF. Originally developed to treat metastatic cancer (by depriving it of its blood supply), bevacizumab is highly effective in causing both anatomic regression of CNVM as well as reversal of CNVM-induced VA loss. Ranibizumab (brand name Lucentis) is a fragment of the bevacizumab antibody, and was developed specifically for treating CNVM.

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

Because of its importance in CNVM formation, VEGF presents a potent target for therapies intended to interdict CNVM. A number of highly effective anti-VEGF compounds have been developed (and more are in the therapeutic pipeline). Bevacizumab (brand name Avastin) is a recombinant monoclonal antibody against VEGF. Originally developed to treat metastatic cancer (by depriving it of its blood supply), bevacizumab is highly effective in causing both anatomic regression of CNVM as well as reversal of CNVM-induced VA loss. Ranibizumab (brand name Lucentis) is a fragment of the bevacizumab antibody, and was developed specifically for treating CNVM. Aflibercept (brand name Eyelea) is a recombinant fusion protein, and works via a different mechanism. Instead of acting as an antibody against VEGF, the aflibercept molecule mimics the VEGF receptor, binding and trapping VEGF that would otherwise bind actual VEGF receptors.

 Key fact #8: VEGF plays a key role in exudative ARMD, and as a result, interdicting VEGF is key in managing it



Fundamentally, the CNVM that defines wet ARMD is a pathologic form of angiogenesis. *Angiogenesis* refers to the cascade of events involved in the formation of new blood vessels. Vascular endothelial growth factor (VEGF) is an extracellular signaling molecule integral to the angiogenesis cascade. Research indicates VEGF plays a causal role in the initiation of CNVM in wet ARMD.

Because of its importance in CNVM formation, VEGF presents a potent target for therapies intended to interdict CNVM. A number of highly effective anti-VEGF compounds have been developed (and more are in the therapeutic pipeline). Bevacizumab (brand name Avastin) is a recombinant monoclonal antibody against VEGF. Originally developed to treat metastatic cancer (by depriving it of its blood supply), bevacizumab is highly effective in causing both anatomic regression of CNVM as well as reversal of CNVM-induced VA loss. Ranibizumab (brand name Lucentis) is a fragment of the bevacizumab antibody, and was developed specifically for treating CNVM. Aflibercept (brand name Eyelea) is a recombinant fusion protein, and works via a different mechanism. Instead of acting as an antibody against VEGF, the aflibercept molecule mimics the VEGF receptor, binding and trapping VEGF that would otherwise bind actual VEGF receptors. All three of these therapies are roughly equivalent in effectiveness, and all have good safety profiles. Each is administered via intravitreal injection.

Key fact #9: Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts



Key fact #9: Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts



The *Age-Related Eye Disease Study* (AREDS) examined whether dietary supplements could impact ARMD. Pts received vitamins C, E, and β –carotene, as well as zinc and copper.

Key fact #9: Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts



The *Age-Related Eye Disease Study* (AREDS) examined whether dietary supplements could impact ARMD. Pts received vitamins C, E, and β –carotene, as well as zinc and copper. The AREDS found that in pts with intermediate or advanced dry ARMD, supplementation reduced the risk of dz progression and/or significant vision loss. (In pts with mild or no ARMD, supplementation conveyed no discernible benefit.)

Key fact #9: Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts



The *Age-Related Eye Disease Study* (AREDS) examined whether dietary supplements could impact ARMD. Pts received vitamins C, E, and β –carotene, as well as zinc and copper. The AREDS found that in pts with intermediate or advanced dry ARMD, supplementation reduced the risk of dz progression and/or significant vision loss. (In pts with mild or no ARMD, supplementation conveyed no discernible benefit.) Of note, β -carotene supplementation was associated with an increased risk of lung Ca in smokers. As smokers comprise a substantial proportion of ARMD pts, this is a significant finding.

Key fact #9: Nonexudative ARMD isn't treatable at present, but a major clinical trial found that micronutrient supplementation reduces the likelihood of conversion to exudative ARMD in at-risk pts



The *Age-Related Eye Disease Study* (AREDS) examined whether dietary supplements could impact ARMD. Pts received vitamins C, E, and β –carotene, as well as zinc and copper. The AREDS found that in pts with intermediate or advanced dry ARMD, supplementation reduced the risk of dz progression and/or significant vision loss. (In pts with mild or no ARMD, supplementation conveyed no discernible benefit.) Of note, β -carotene supplementation was associated with an increased risk of lung Ca in smokers. As smokers comprise a substantial proportion of ARMD pts, this is a significant finding. Happily, a follow-up study (*AREDS2*) found that for β -carotene could be replaced with xanthophylls (specifically, lutein and zeaxanthin) without loss of efficacy (and with no increased risk of lung Ca).



That's it! Go through this slide-set a couple of times (at least) until you feel like you have a handle on it. When you're ready, do slide-set *R69*, which covers this material in a Q&A format (and more detail).